Original Source(s)
Related Content
FDA grants Temab-A dual Breakthrough status
The designations cover refractory metastatic CRC and previously treated c-Met–expressing NSCLC.
by Mouj Hijazi
October 7, 2026
-
3 min
FDA approves olanzapine injection for schizophrenia
All 3 monthly doses improved schizophrenia symptoms versus placebo in the phase 3 SOLARIS trial.
by Mouj Hijazi
October 9, 2026
-
3 min
Cumulative training load may signal musculoskeletal injury
Wearable sensor measures showed associations with musculoskeletal injury, but evidence certainty remained very low.
October 12, 2026
-
4 min